Literature DB >> 12123834

Characterisation of a novel mouse liver aldo-keto reductase AKR7A5.

Alison Hinshelwood1, Gail McGarvie, Elizabeth Ellis.   

Abstract

We have characterised a novel aldo-keto reductase (AKR7A5) from mouse liver that is 78% identical to rat aflatoxin dialdehyde reductase AKR7A1 and 89% identical to human succinic semialdehyde (SSA) reductase AKR7A2. AKR7A5 can reduce 2-carboxybenzaldehyde (2-CBA) and SSA as well as a range of aldehyde and diketone substrates. Western blots show that it is expressed in liver, kidney, testis and brain, and at lower levels in skeletal muscle, spleen heart and lung. The protein is not inducible in the liver by dietary ethoxyquin. Immunodepletion of AKR7A5 from liver extracts shows that it is one of the major liver 2-CBA reductases but that it is not the main SSA reductase in this tissue.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12123834     DOI： 10.1016/s0014-5793(02)02982-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

2.  Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls.

Authors:  Mahavir Singh; Aniruddh Kapoor; Aruni Bhatnagar
Journal:  Chem Biol Interact       Date:  2015-01-02       Impact factor: 5.192

3.  Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes.

Authors:  Matthew Spite; Shahid P Baba; Yonis Ahmed; Oleg A Barski; Kanchan Nijhawan; J Mark Petrash; Aruni Bhatnagar; Sanjay Srivastava
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

4.  Testing an aflatoxin B1 gene signature in rat archival tissues.

Authors:  B Alex Merrick; Scott S Auerbach; Patricia S Stockton; Julie F Foley; David E Malarkey; Robert C Sills; Richard D Irwin; Raymond R Tice
Journal:  Chem Res Toxicol       Date:  2012-05-04       Impact factor: 3.739

5.  Zizyphus spina-christi extract protects against aflatoxin B1-initiated hepatic carcinogenicity.

Authors:  Mosaad A Abdel-Wahhab; Enayat A Omara; Mona M Abdel-Galil; Nabila S Hassan; Somaia A Nada; Ataa Saeed; Magdy M el-Sayed
Journal:  Afr J Tradit Complement Altern Med       Date:  2007-02-16

6.  Conversion of methylglyoxal to acetol by Escherichia coli aldo-keto reductases.

Authors:  Junsang Ko; Insook Kim; Seokho Yoo; Bumchan Min; Kyungmin Kim; Chankyu Park
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

7.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

8.  Tissue distribution, ontogeny, and chemical induction of aldo-keto reductases in mice.

Authors:  Matthew Pratt-Hyatt; Andrew J Lickteig; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2013-05-09       Impact factor: 3.922

9.  Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver.

Authors:  Kai Connie Wu; Julia Yue Cui; Curtis D Klaassen
Journal:  PLoS One       Date:  2012-07-12       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.